Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort.
暂无分享,去创建一个
F. Moosig | R. Vonthein | B. Nölle | W. Gross | E. Reinhold-Keller | J. Holle | K. Herrmann | S. Schinke | M. Both | F. Henes | J. Schirmer | Marvin N. Wright | A. Arlt
[1] F. Caputo,et al. Microscopic polyangiitis associated with pulmonary fibrosis , 2015, Clinical Rheumatology.
[2] Shigao Huang,et al. Cord Blood-Derived Cytokine-Induced Killer Cellular Therapy Plus Radiation Therapy for Esophageal Cancer , 2014, Medicine.
[3] S. Kikuchi,et al. Retrospective analysis of factors predicting end-stage renal failure or death in patients with microscopic polyangiitis with mainly renal involvement , 2014, Clinical and Experimental Nephrology.
[4] Kaifeng Xu,et al. A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China , 2014, BMC Pulmonary Medicine.
[5] 栄一 末松. 血管炎の新分類2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides , 2013 .
[6] H. Makino,et al. Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan , 2013, The Journal of Rheumatology.
[7] Y. Kondoh,et al. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. , 2012, Respiratory medicine.
[8] H. Makino,et al. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan , 2012, Clinical and Experimental Nephrology.
[9] N. Arden,et al. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. , 2011, Rheumatology.
[10] P. Ind,et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. , 2011, Rheumatology.
[11] J. del Pino-Montes,et al. Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. , 2011, Rheumatology.
[12] D. Jayne,et al. Management of alveolar hemorrhage in lung vasculitides. , 2011, Seminars in respiratory and critical care medicine.
[13] P. Höglund,et al. Long-term patient survival in ANCA-associated vasculitis , 2010, Annals of the rheumatic diseases.
[14] L. Jacobsson,et al. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.
[15] M. Kokosi,et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis , 2009, European Respiratory Journal.
[16] P. Nightingale,et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis , 2009, Annals of the rheumatic diseases.
[17] V. Tesar,et al. Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.
[18] Z. Amoura,et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature , 2008, Annals of the rheumatic diseases.
[19] V. Cottin,et al. ANCA-associated lung fibrosis: analysis of 17 patients. , 2008, Respiratory medicine.
[20] H. Raspe,et al. EULAR recommendations for the management of primary small and medium vessel vasculitis , 2008, Annals of the Rheumatic Diseases.
[21] H. Raspe,et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.
[22] L. Cattaneo,et al. Peripheral neuropathy in Wegener’s granulomatosis, Churg–Strauss syndrome and microscopic polyangiitis , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[23] H. Raspe,et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis , 2006, Annals of the rheumatic diseases.
[24] D. Scott,et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.
[25] U. Maggiore,et al. Outcome and prognostic factors during the course of primary small-vessel vasculitides. , 2006, The Journal of rheumatology.
[26] V. Tesar,et al. Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement , 2005, Kidney and Blood Pressure Research.
[27] D. Scott,et al. Primary systemic vasculitis: clinical features and mortality. , 2005, QJM : monthly journal of the Association of Physicians.
[28] G. Sobue,et al. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. , 2002, The Journal of rheumatology.
[29] M. Heller,et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.
[30] J. Amouroux,et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. , 1999, Arthritis and rheumatism.
[31] J. Ranstam,et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. , 1998, Journal of the American Society of Nephrology : JASN.
[32] C. Gordon,et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.
[33] R. Moots,et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.
[34] Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: A Series of 49 Patients and Review of the Literature: Erratum. , 2015, Medicine.
[35] H. Doll,et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. , 2015, Annals of the rheumatic diseases.
[36] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[37] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[38] E. Daugas,et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. , 2012, Clinical and experimental rheumatology.
[39] M. Heller,et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. , 2011, Arthritis and rheumatism.
[40] 安藤 ゆみ子. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease : CT findings in 51 patients , 2007 .
[41] K. De Groot,et al. Development and validation of a disease extent index for Wegener's granulomatosis. , 2001, Clinical nephrology.
[42] J. Nossent,et al. Fibrosing alveolitis predating microscopic polyangiitis. , 1999, Scandinavian journal of rheumatology.
[43] R. Falk,et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.
[44] R. Falk,et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.